BI drug gets priority review

Share this article:

The FDA bestowed priority review status on Boehringer Ingelheim's experimental idiopathic pulmonary fibrosis treatment nintedanib. The treatment also has orphan drug status—the progressive and fatal lung disease is a rare condition which affects around 132,000 patients in the US.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION